Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...

Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study ...

WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 ...

Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.

GSK returns rights to Wave's RNA editing program for AATD; Cassidy took on RFK Jr. over vaccines. Now Kennedy's followers are ...

Ltd (NASDAQ:WVE) stock rose 2.1% Monday after the clinical-stage biotechnology company announced it has regained full rights to WVE-006, its investigational RNA editing therapy for alpha-1 antitrypsin ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Korro Bio, Inc. is next on our list of best ...

US biotech Wave Life Sciences has regained full rights to WVE-006 from British pharma GSK, bringing the RNA-editing therapy for alpha-1 antitrypsin deficiency back in-house as it prepares for ...

With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...